Mark Titus

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

28h-index3.0kcitations166works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(97), Cancer, Lipids, and Metabolism(33), Cancer, Hypoxia, and Metabolism(28), Hormonal and reproductive studies(26), Extracellular vesicles in disease(21)

Publications166 total

Supplementary Figures 1-4 from Subtype and Site Specific–Induced Metabolic Vulnerabilities in Prostate Cancer
2025Open Access
Abstract 2143: Sequential anti-folate (pemetrexed) and anti-PD-L1 (avelumab) combination therapy in patients with previously treated MTAP-deficient advanced urothelial cancer: Clinical outcomes and immune correlative analyses
Cancer Research·2025
Oxidative Phosphorylation Inhibition in Different Prostate Cancer Models and the Interplay with Androgen Receptor Signaling
2024Open Access
Combining Hyperpolarized Magnetic Resonance and Positron Emission Tomography to Interrogate Prostate Cancer Metabolism
Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition·2024
Identifying the Metabolic Signatures of PPARD-Overexpressing Gastric Tumors by HP MRI and Metabolomics
Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition·2024
Body composition as a determinant of the therapeutic index with androgen signaling inhibition
Prostate Cancer and Prostatic Diseases·2024· 8 cited
Data from Subtype and Site Specific–Induced Metabolic Vulnerabilities in Prostate Cancer
2024Open Access
Supplementary Figure 5 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
2023Open Access
Data from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
2023Open Access
Supplementary Figure 2 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
2023Open Access
Supplementary Figure 1 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
2023Open Access
FIGURE 2 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
2023Open Access
FIGURE 6 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
2023Open Access
Supplementary Figure 4 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
2023Open Access
Supplementary Figure 5 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
2023Open Access
FIGURE 4 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
2023Open Access
Supplementary Figure 2 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
2023Open Access
FIGURE 5 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
2023Open Access
Supplementary Figure 3 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
2023Open Access
Supplementary Figure 4 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
2023Open Access
page 1 of 9Next →

Frequent Co-authors

Christopher J. Logothetis(19), Eleni Efstathiou(15), James L. Mohler(13), Anh Hoang(12), Patricia Troncoso(11), Sijin Wen(8), Amado J. Zurita(7), Sumankalai Ramachandran(7), Daniel E. Frigo(5), Paul G. Corn(5), Kenneth B. Tomer(4), Arturo Molina(4), O. Harris Ford(4), John W. Davis(4), Fred B. Lih(3), Μαρία Κάρλου(3), Ana M. Aparicio(3), Elizabeth Wilson(3), Alexander J. Lazar(3), P. Andrew Futreal(3)